Arthropathy; Traumatic, Arthroplasty Complications, Rotator Cuff Injuries, Shoulder Pain
Conditions
Brief summary
The objectives of this study are to confirm safety, performance and clinical benefits of the ASHCOM Shoulder System and its related instruments by analysis of standard scoring systems, radiographs and adverse event records.
Detailed description
This study is a multicenter, prospective, non-controlled Post-Market Clinical Follow-up study involving orthopaedic surgeons skilled in reverse shoulder arthroplasty procedures. A minimum of three study centers will be involved. A total number of 97 implants will be included into the study. The primary endpoint is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. The secondary endpoint is defined by the performance and clinical benefits of the ASHCOM Shoulder System at 5 years, which is assessed by the Constant and Murley score. Assessments of the overall pain, functional performance, survival, quality of life and radiographic parameters of all enrolled study subjects will be evaluated in addition.
Interventions
Reverse Shoulder Arthroplasty
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient is capable of understanding the doctor's explanations, following his instructions and is able to participate in the follow-up program. * Patient has given written consent to take part in the study by signing the Patient Consent Form. * Patient is 18-80 years of age, inclusive. * Patient is skeletally mature. * Patient requires a primary, fracture or revision reverse total shoulder replacement for the relief of pain and has significant disability due to gross rotator cuff deficiency. * Patient's joint is anatomically and structurally suited to receive the selected implants. * Patient has a functional deltoid muscle.
Exclusion criteria
* Patient is unwilling or unable to give consent or to comply with the follow-up program. * Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them. * Patient is known to be pregnant or breastfeeding. * Patient is a vulnerable subject. * Patient meets at least one of the contraindications: * Signs of infection * Significant injury to the upper brachial plexus * Non-functional deltoid muscle * Insufficient quality and/or quantity of glenoid or humeral bone * Any neuromuscular or vascular disease compromising the affected limb that would endanger the success of the intervention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival of Implant System (Kaplan Meier) | 3 years | The primary endpoint is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method. Due to early study termination, the survival of the implant was analyzed at 3 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM) | Pre-operative (baseline), 1 year, 2 years post-operative | The secondary endpoint of this study is defined by the performance and clinical benefits of the ASHCOM Shoulder System at 5 years, which is assessed by the Constant and Murley score. Due to early study termination, the Constant and Murley Score was assessed at 2 years. The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points. The minimum score is 0 points (worst outcome), the maximum score possible is 100 points (best outcome). |
| Oxford Shoulder Score (OSS) | Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative | The Oxford Shoulder Score (OSS) is a patient-reported outcome questionnaire that was developed to specifically assess the patient's perspective of outcome following total shoulder arthroplasty. The OSS consists of twelve questions covering function and pain associated with the shoulder. To calculate the total score, each question is scored from 0 (worst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible and a minimum of 0, representing the worst possible. The outcome score can be categorized as: Satisfactory Joint Function: 40 - 48, Moderate-Mild Arthritis: 30 - 39, Moderate-Severe Arthritis: 20 - 29, Severe Arthritis: 0 - 19. |
| EQ-5D-5L Score | Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative | The EQ-5D-5L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes 5 questions referring to mobility, self-care, daily activities, pain/discomfort and anxiety/depression. Each question can be answered in five ways, indicating no, slight, moderate, severe problems or inability to complete the task. In the derived EQ-5D-5L score, the highest score is 1 and the lowest score is -0.573. It included the Health State, which is a self-reported assessment about the patient's health on that day at a VAS from 0 to 100 with 100 being the best health one can imagine and 0 the worst. |
| Subjective Shoulder Value (SSV) | Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative | The Subjective Shoulder Value (SSV) is a single point, subjective estimate of a patient's condition. The patient is asked to rate the functionality of their operated shoulder on a scale of 0% - 100% of normal. |
| Radiographic Parameters | 2 years post-operative | Radiographic parameters: X-rays have been evaluated for radiolucency, osteolysis, atrophy, hypertrophy, osteophytes (glenoid), component migration (humeral stem subsidence / glenoid component migration), heterotopic ossification and scapular notching |
Countries
Italy
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem Subjects implanted with the ASHCOM Shoulder System and an uncemented humeral stem
ASHCOM Shoulder System: Reverse Shoulder Arthroplasty | 22 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem Subjects implanted with the ASHCOM Shoulder System and a fracture humeral stem
ASHCOM Shoulder System: Reverse Shoulder Arthroplasty | 2 |
| Total | 24 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 1 | 0 |
| Overall Study | Early study termination | 21 | 2 |
Baseline characteristics
| Characteristic | ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Total |
|---|---|---|---|
| Age, Continuous | 70.14 years STANDARD_DEVIATION 6.14 | 72.5 years STANDARD_DEVIATION 3.54 | 70.33 years STANDARD_DEVIATION 5.95 |
| Preop BMI | 26.34 kg/m^2 STANDARD_DEVIATION 2.46 | 22.2 kg/m^2 STANDARD_DEVIATION 1.13 | 25.99 kg/m^2 STANDARD_DEVIATION 2.64 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment Italy | 22 participants | 2 participants | 24 participants |
| Sex: Female, Male Female | 10 Participants | 2 Participants | 12 Participants |
| Sex: Female, Male Male | 12 Participants | 0 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 22 | 0 / 2 |
| other Total, other adverse events | 0 / 22 | 0 / 2 |
| serious Total, serious adverse events | 1 / 22 | 0 / 2 |
Outcome results
Survival of Implant System (Kaplan Meier)
The primary endpoint is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method. Due to early study termination, the survival of the implant was analyzed at 3 years.
Time frame: 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Survival of Implant System (Kaplan Meier) | 21 Participants |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Survival of Implant System (Kaplan Meier) | 2 Participants |
EQ-5D-5L Score
The EQ-5D-5L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes 5 questions referring to mobility, self-care, daily activities, pain/discomfort and anxiety/depression. Each question can be answered in five ways, indicating no, slight, moderate, severe problems or inability to complete the task. In the derived EQ-5D-5L score, the highest score is 1 and the lowest score is -0.573. It included the Health State, which is a self-reported assessment about the patient's health on that day at a VAS from 0 to 100 with 100 being the best health one can imagine and 0 the worst.
Time frame: Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative
Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit and for one patient the score was not collected at the 3-6 months and 1 year follow-up visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | EQ-5D-5L Score | 3-6 Months | 0.79 score on a scale | Standard Deviation 0.11 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | EQ-5D-5L Score | 2 Year | 0.99 score on a scale | Standard Deviation 0.05 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | EQ-5D-5L Score | 1 Year | 0.97 score on a scale | Standard Deviation 0.08 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | EQ-5D-5L Score | 3 Year | 1.0 score on a scale | Standard Deviation 0.01 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | EQ-5D-5L Score | Preop | 0.22 score on a scale | Standard Deviation 0.16 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | EQ-5D-5L Score | 3 Year | 0.97 score on a scale | Standard Deviation 0.04 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | EQ-5D-5L Score | Preop | 0.06 score on a scale | Standard Deviation 0.07 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | EQ-5D-5L Score | 3-6 Months | 0.56 score on a scale | Standard Deviation 0.15 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | EQ-5D-5L Score | 1 Year | 0.67 score on a scale | Standard Deviation 0.17 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | EQ-5D-5L Score | 2 Year | 0.88 score on a scale | Standard Deviation 0 |
Oxford Shoulder Score (OSS)
The Oxford Shoulder Score (OSS) is a patient-reported outcome questionnaire that was developed to specifically assess the patient's perspective of outcome following total shoulder arthroplasty. The OSS consists of twelve questions covering function and pain associated with the shoulder. To calculate the total score, each question is scored from 0 (worst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible and a minimum of 0, representing the worst possible. The outcome score can be categorized as: Satisfactory Joint Function: 40 - 48, Moderate-Mild Arthritis: 30 - 39, Moderate-Severe Arthritis: 20 - 29, Severe Arthritis: 0 - 19.
Time frame: Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative
Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit and for one patient the score was not collected at the 2 years follow-up.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Oxford Shoulder Score (OSS) | 3-6 Month | 41.81 score on a scale | Standard Deviation 3.97 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Oxford Shoulder Score (OSS) | 2 Year | 47.8 score on a scale | Standard Deviation 0.52 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Oxford Shoulder Score (OSS) | 1 Year | 47.62 score on a scale | Standard Deviation 0.92 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Oxford Shoulder Score (OSS) | 3 Year | 48.0 score on a scale | Standard Deviation 0 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Oxford Shoulder Score (OSS) | Preop | 6.27 score on a scale | Standard Deviation 3.56 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Oxford Shoulder Score (OSS) | 3 Year | 47.5 score on a scale | Standard Deviation 0.71 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Oxford Shoulder Score (OSS) | Preop | 5.5 score on a scale | Standard Deviation 7.78 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Oxford Shoulder Score (OSS) | 3-6 Month | 32.5 score on a scale | Standard Deviation 0.71 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Oxford Shoulder Score (OSS) | 1 Year | 45.5 score on a scale | Standard Deviation 0.71 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Oxford Shoulder Score (OSS) | 2 Year | 48.0 score on a scale | Standard Deviation 0 |
Radiographic Parameters
Radiographic parameters: X-rays have been evaluated for radiolucency, osteolysis, atrophy, hypertrophy, osteophytes (glenoid), component migration (humeral stem subsidence / glenoid component migration), heterotopic ossification and scapular notching
Time frame: 2 years post-operative
Population: ASHCOM Shoulder System subjects - Uncemented humeral stem: The number analyzed at 2 years is 21, as one patient passed away prior to the 3-6 month visit.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Radiographic Parameters | Any radiographic findings - Yes: | 0 Participants |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Radiographic Parameters | Any radiographic findings - No: | 21 Participants |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Radiographic Parameters | Any radiographic findings - Yes: | 0 Participants |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Radiographic Parameters | Any radiographic findings - No: | 2 Participants |
Subjective Shoulder Value (SSV)
The Subjective Shoulder Value (SSV) is a single point, subjective estimate of a patient's condition. The patient is asked to rate the functionality of their operated shoulder on a scale of 0% - 100% of normal.
Time frame: Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative
Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit. For one patient the score was not collected at the 3-6 months follow-up visit and for two patients at the 1 year follow-up visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Subjective Shoulder Value (SSV) | 3-6 Months | 76.5 percentage of normal | Standard Deviation 9.47 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Subjective Shoulder Value (SSV) | 2 Year | 94.74 percentage of normal | Standard Deviation 7.35 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Subjective Shoulder Value (SSV) | 1 Year | 89.74 percentage of normal | Standard Deviation 9.64 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Subjective Shoulder Value (SSV) | 3 Year | 96.19 percentage of normal | Standard Deviation 5.46 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | Subjective Shoulder Value (SSV) | Preop | 25.0 percentage of normal | Standard Deviation 14.72 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Subjective Shoulder Value (SSV) | 3 Year | 97.5 percentage of normal | Standard Deviation 3.54 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Subjective Shoulder Value (SSV) | Preop | 10.0 percentage of normal | Standard Deviation 14.14 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Subjective Shoulder Value (SSV) | 3-6 Months | 62.5 percentage of normal | Standard Deviation 3.54 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Subjective Shoulder Value (SSV) | 1 Year | 77.5 percentage of normal | Standard Deviation 3.54 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | Subjective Shoulder Value (SSV) | 2 Year | 90.0 percentage of normal | Standard Deviation 0 |
The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)
The secondary endpoint of this study is defined by the performance and clinical benefits of the ASHCOM Shoulder System at 5 years, which is assessed by the Constant and Murley score. Due to early study termination, the Constant and Murley Score was assessed at 2 years. The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points. The minimum score is 0 points (worst outcome), the maximum score possible is 100 points (best outcome).
Time frame: Pre-operative (baseline), 1 year, 2 years post-operative
Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit and for one patient the score was not collected at the 2 years follow-up.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM) | Preop | 7.91 score on a scale | Standard Deviation 8.18 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM) | 1 year | 74.0 score on a scale | Standard Deviation 12.55 |
| ASHCOM Shoulder System Subjects - Uncemented Humeral Stem | The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM) | 2 years | 82.95 score on a scale | Standard Deviation 8.65 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM) | Preop | 5.0 score on a scale | Standard Deviation 7.07 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM) | 1 year | 55.0 score on a scale | Standard Deviation 4.24 |
| ASHCOM Shoulder System Subjects - Fracture Humeral Stem | The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM) | 2 years | 70.5 score on a scale | Standard Deviation 9.19 |